EXPERIENCE• Biomarker discovery in development of cell signaling-based companion diagnostics (CDx) for small molecule and monoclonal antibody cancer drugs• Optimization of automated drug modulation platform enabling live cell signaling-based CDx (SnapPath® Cancer Diagnostic System)• Profiling dynamic biomarkers from live tumor samples and cell lines for predicting drug response in solid tumor cancers• Pharmacodynamic drug synergism studies using novel molecularly targeted agent combinations• Optimization of protein assays and plate-based multiplex assays• Optimization of ex vivo sample processing and drug modulation methods for live cell biopsies and patient-derived xenografts • Troubleshooting of automated, fluidics-based robotic platforms• Generation of company SOP documents• Assisted writing of proposals for successfully funded NCI and NIH grants• Manuscript writing for successfully published research• Collaborated with team of multi-disciplined scientists & engineers on parallel projects• Conducted weekly data briefings with research team and chief managers• Collaborated with pathologists procuring clinical samples (Johns Hopkins, Baltimore, MD)• Trained and managed technician-level researchers in small groups• Managed upkeep of assay platforms and materials stocks for research teamTECHNIQUES & SKILLS• Small molecule, monoclonal antibody and immunotherapy cancer therapeutic studies • Cytotoxicity and cell viability assays (MTT, WST-8, colony formation)• Immunoblotting (protein expression qualitative/quantitative analysis)• Multiplex immunoassays• Tissue culture technique (maintenance of cancer cell lines)• ICC biomarkers staining• Disaggregation and enrichment of complex samples from patient biopsies and patient-derived xenograft• Cell and protein purification (immunoprecipitation)• Live cell microscopy and photo imaging• Data Analysis Software: Microsoft Office, ImageJ, GraphPad Prism, Affinity Photo/Designer, Mendeley Reference

Master's Student ResearcherMain Project Title: “Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in Non-small cell lung cancer.”EXPERIENCE• Designed innovative studies in protein receptor crosstalk and small molecule drug synergism• Identified novel lung cancer and melanoma drug response and resistance targets• Data published as manuscript in PLOS ONE (2015) and others• Data communicated as abstracts and poster presentations at annual meetings of The American Association for Cancer Research and The American Society for Mass Spectrometry• Assisted and shadowed a Thermo Fisher Scientific team discovering novel lung cancer drug biomarkers using peptide tagging and mass spectrometry quantification (Thermo Fisher Scientific, Rockford, IL)